NCT00986882COMPLETEDanonymous

A Double-blind, Randomized, Single Dose, Placebo Controlled, Three Part Study to Evaluate the Safety and Tolerability, Efficacy and Dose Response of SAF312 in Postoperative Dental Pain Patients

Sponsor

Source record

Novartis

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

SAF312A, Placebo, Ibuprofen

Indication / condition

AI-normalized

Postoperative Pain

Intervention

Source record

SAF312A, Placebo, Ibuprofen

Related intelligence directories

Indication directory: Postoperative Pain Modality directory: small molecule Target directory: SAF312A

Source & freshness

Source record

NCT ID

NCT00986882

Original source

ClinicalTrials.gov

Source last updated

Dec 19, 2020

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT00986882

Title

A Double-blind, Randomized, Single Dose, Placebo Controlled, Three Part Study to Evaluate the Safety and Tolerability, Efficacy and Dose Response of SAF312 in Postoperative Dental Pain Patients

Sponsor

Novartis

Status

COMPLETED

Phase

PHASE2

Condition raw

Postoperative Pain

Condition normalized

Postoperative Pain

Modality raw

small molecule

Modality normalized

small molecule

Target raw

SAF312A, Placebo, Ibuprofen

Target normalized

SAF312A, Placebo, Ibuprofen

Interventions

SAF312A, Placebo, Ibuprofen

Public preview

Source record

The study will assess the analgesic efficacy and safety and tolerability of a single oral dose of SAF312 in postoperative dental pain patients after 3rd molar extraction.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Double-blind, Randomized, Single Dose, Placebo Controlled, Three Part Study to Evaluate the Safety and Tolerability, Efficacy and Dose Response of SAF312 in Postoperative Dental Pain Patients

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT00986882

Status

COMPLETED

Phase

PHASE2

Sponsor

Novartis

Executive brief

Investment-Ready Snapshot

The study will assess the analgesic efficacy and safety and tolerability of a single oral dose of SAF312 in postoperative dental pain patients after 3rd molar extraction.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedDec 19, 2020

Internal syncJun 09, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00986882

Indication

Postoperative Pain

Modality

small molecule

Target

SAF312A, Placebo, Ibuprofen

Intervention

SAF312A, Placebo, Ibuprofen

Source record